Human trial

Tesamorelin

Reducing visceral fat in a specific approved indication, with formal human trial data.

A 15-second vertical explainer plays in this frame when the file is published.

What it is

Tesamorelin is a growth-hormone-releasing hormone analogue. It has formal human trial data and an approved use aimed at reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That indication is specific. It is not a general fat-loss approval. Confirm the current label with a licensed prescriber before treating any wording here as the last word.

Studied for

  • Reducing excess visceral fat in the specific population named on its label.
  • The growth-hormone axis, which is the pathway the trials measured.

The evidence

Human trial. The record here is a formal drug programme with measured human outcomes, not a gym protocol. The approval does not extend itself to every goal people bring to a growth-hormone conversation.

What this page will not do

  • We will not restate this as a cosmetic fat-loss plan.
  • We do not give doses or hormone-axis targets.
  • Anything hormone-adjacent belongs with a physician who can order and read the right labs.

Still open

  • Whether the labeled indication matches the question you actually have.
  • What the current label says this month — labels change, and this page is not the label.

Educational content only. This page does not diagnose, treat, cure, or prevent anything, and it is not a dose. Talk with a licensed physician before starting, stopping, or changing any medication. Library reviewed November 2026.